Related Experiment Videos
Overview and perspectives of antihypertensive treatment
1Istituto di Clinica Medica Generale e Terapia Medica, Università di Milano, Italy.
Insights
Treating severe hypertension offers significant benefits, while mild cases show smaller gains unless other risk factors are present. Antihypertensive therapy is a key part of a broader cardiovascular disease prevention strategy.
Area of Science:
- Cardiology
- Pharmacology
- Preventive Medicine
Background:
- Antihypertensive trials indicate substantial benefits in severe hypertension, with smaller gains in mild cases.
- Benefit is greater in mild hypertension when co-occurring risk factors like dyslipidemia and glucose intolerance are present.
- Cardiovascular disease prevention requires a multifaceted approach, with antihypertensive therapy as a crucial component.
Purpose of the Study:
- To evaluate the suitability of different antihypertensive drug classes for patients with hypertension and co-existing risk factors.
- To assess the impact of metabolic side effects of antihypertensives on overall treatment benefits.
- To guide the selection of antihypertensive agents considering patient-specific risk profiles.
Main Methods:
- Review and analysis of existing antihypertensive trial data.
- Comparison of metabolic profiles of various antihypertensive drug classes (thiazide diuretics, beta-blockers, calcium antagonists, ACE-inhibitors, alpha-blockers).
- Assessment of potential offsetting effects of drug-induced metabolic changes on blood pressure reduction benefits.
Main Results:
- Thiazide diuretics and beta-blockers may adversely affect lipid and glucose metabolism.
- Calcium antagonists and ACE-inhibitors are generally lipid-neutral.
- Alpha-blockers may have favorable effects on lipid metabolism, though clinical impact requires further proof.
Conclusions:
- The choice of antihypertensive medication should consider potential metabolic side effects, especially in patients with dyslipidemia or glucose intolerance.
- Metabolic side effects of some drugs might counteract blood pressure-lowering benefits.
- Future research should focus on antihypertensive drugs with favorable metabolic profiles for comprehensive cardiovascular risk management.
Abstract:
An overview of antihypertensive trials shows that, when absolute rather than relative measures of benefit are considered, a large benefit is derived from treating severe hypertension, whereas in mild hypertension the rate of prevented morbid events is relatively small. However, a greater benefit is observed when a mildly elevated diastolic blood pressure is associated with other risk factors. Thus, antihypertensive therapy in the 1990s needs to be regarded as a component, albeit an important one, in a multiple-strategy approach to prevention and reversal of cardiovascular diseases. At a time when many different classes of antihypertensive agents are available, it is reasonable to ask whether some classes are more suitable than others for the treatment of patients with hypertension and concomitant risk factors such as dyslipidaemias and reduced glucose tolerance. It is well known that thiazide diuretics and beta-blockers have potentially adverse effects on lipid and glucose metabolism, that calcium antagonists and ACE-inhibitors are lipid neutral and that alpha-blockers have potentially favourable effects. Although the real impact of some of these changes is unproven, it is possible that one or more of the metabolic side effects of drugs such as diuretics and beta-blockers may offset some of the benefits of reduced blood pressure. Extensive testing of antihypertensive drugs with a favourable profile can be foreseen in the 1990s.